Balanced Outlook on Edwards Lifesciences: Navigating FDA Approval and Capacity Constraints

Leerink Partners analyst Mike Kratky has reiterated their neutral stance on EW stock, giving a Hold rating on May 2.

Mike Kratky’s rating is based on several factors surrounding Edwards Lifesciences’ recent FDA approval for their SAPIEN 3 platform for asymptomatic patients. While this approval is seen as a positive development due to the potential for significant commercial opportunities, there are concerns about hospital capacity constraints. These constraints, influenced by emerging structural heart therapies, have previously affected the US TAVR volumes, potentially limiting the immediate impact of this approval.
Despite these near-term challenges, survey responses indicate a potential increase in TAVR volumes by 8%, 13%, and 15% over the next three years, which could surpass current expectations. However, Kratky remains cautious in the short term, balancing the potential long-term growth against the current market conditions and capacity issues. The Hold rating reflects this balanced view, acknowledging both the promising growth prospects and the existing challenges.

EW’s price has also changed moderately for the past six months – from $67.540 to $75.180, which is a 11.31% increase.